[Invasive aspergillosis in "nonimmunocompromised" patients (case reports)].

Q3 Medicine Klinicka mikrobiologie a infekcni lekarstvi Pub Date : 2019-06-01
Ľbomír Soják
{"title":"[Invasive aspergillosis in \"nonimmunocompromised\" patients (case reports)].","authors":"Ľbomír Soják","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Invasive aspergillosis (IA) is a major cause of morbidity and mortality in immunocompromised patients. Given the rising numbers of patients at risk of opportunistic infections, there has been a significant increase in Aspergillus infections in recent years. Patients most at risk are mainly those with prolonged neutropenia or receiving long-term corticosteroid or other immunosuppressive thera pies and those with impaired pulmonary defense. Relatively recently, critically ill patients without traditional risk factors were also classified as at-risk, that is patients in intensive care units, those with chronic obstructive pulmonary disease, post-flu and so on. Chronic obstructive pulmonary disease is one of the most common predisposing conditions due to frequent Aspergillus airway colonization. Other significant risk factors for IA are decompensated liver disease and cirrhosis, AIDS, corticosteroid treatment, impaired mucociliary transport after cure from pneumonia (both bacterial and viral), immune deficiency in long-lasting diseases and autoimmune disorders. Additionally, various immunosuppressive drugs increase the risk of IA (e.g. tumor necrosis factor blockers). The case reports describe two patients who developed disseminated aspergillosis after a severe illness, with the right diagnosis being made only at autopsy. The author´s aim is to draw attention to the need to consider IA also in patients who initially do not appear to be at risk for disseminated fungal infection.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"25 2","pages":"43-47"},"PeriodicalIF":0.0000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicka mikrobiologie a infekcni lekarstvi","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Invasive aspergillosis (IA) is a major cause of morbidity and mortality in immunocompromised patients. Given the rising numbers of patients at risk of opportunistic infections, there has been a significant increase in Aspergillus infections in recent years. Patients most at risk are mainly those with prolonged neutropenia or receiving long-term corticosteroid or other immunosuppressive thera pies and those with impaired pulmonary defense. Relatively recently, critically ill patients without traditional risk factors were also classified as at-risk, that is patients in intensive care units, those with chronic obstructive pulmonary disease, post-flu and so on. Chronic obstructive pulmonary disease is one of the most common predisposing conditions due to frequent Aspergillus airway colonization. Other significant risk factors for IA are decompensated liver disease and cirrhosis, AIDS, corticosteroid treatment, impaired mucociliary transport after cure from pneumonia (both bacterial and viral), immune deficiency in long-lasting diseases and autoimmune disorders. Additionally, various immunosuppressive drugs increase the risk of IA (e.g. tumor necrosis factor blockers). The case reports describe two patients who developed disseminated aspergillosis after a severe illness, with the right diagnosis being made only at autopsy. The author´s aim is to draw attention to the need to consider IA also in patients who initially do not appear to be at risk for disseminated fungal infection.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[非免疫功能低下患者的侵袭性曲霉病(病例报告)]。
侵袭性曲霉病(IA)是免疫功能低下患者发病和死亡的主要原因。鉴于越来越多的患者面临机会性感染的风险,近年来曲霉感染有显著增加。最危险的患者主要是长期中性粒细胞减少或长期接受皮质类固醇或其他免疫抑制治疗的患者以及肺防御受损的患者。最近,没有传统危险因素的危重患者也被列为高危患者,即重症监护病房的患者、慢性阻塞性肺病患者、流感后患者等。慢性阻塞性肺疾病是最常见的易感条件之一,由于频繁的曲霉气道定植。IA的其他重要危险因素包括失代偿性肝病和肝硬化、艾滋病、皮质类固醇治疗、肺炎(细菌性和病毒性)治愈后粘膜纤毛运输受损、长期疾病的免疫缺陷和自身免疫性疾病。此外,各种免疫抑制药物(如肿瘤坏死因子阻滞剂)会增加IA的风险。病例报告描述了两名在严重疾病后出现播散性曲霉病的患者,只有在尸检时才能做出正确的诊断。作者的目的是提请注意,需要考虑IA患者最初似乎没有播散性真菌感染的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Klinicka mikrobiologie a infekcni lekarstvi
Klinicka mikrobiologie a infekcni lekarstvi Medicine-Infectious Diseases
CiteScore
0.40
自引率
0.00%
发文量
0
期刊最新文献
[Resistance of bacterial pathogens isolated from the lower respiratory tract and their clonality in intensive care patients in a post-COVID-19 period]. [A case of botulism in the Czech Republic and current possibilities for detecting the neurotoxin produced by Clostridium botulinum]. [Microbiological methods for identification of the etiological agents of bloodstream infections with focus on the T2Bacteria Panel]. [Pseudomonas aeruginosa virulence factors as a therapeutic target in multidrug-resistant strains]. [Respiratory manifestations of post-COVID syndrome].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1